Dexamethasone and hypertension in preterm infants

Area of Science:

• Neonatal Medicine
• Pediatric Pharmacology
• Cardiovascular Physiology in Neonates

Background:

• Very preterm infants often require dexamethasone for chronic lung disease (CLD).
• The cardiovascular effects of dexamethasone in this vulnerable population are not fully understood.
• Monitoring blood pressure is crucial during and after steroid therapy.

Purpose of the Study:

• To examine the magnitude and duration of dexamethasone's effect on systolic blood pressure in very preterm infants with CLD.
• To assess the need for vigilant blood pressure monitoring during and after dexamethasone treatment.

Main Methods:

• A within-infant control study design was used in 13 very preterm infants (median gestational age 25 weeks) with CLD.
• Systolic blood pressure was monitored throughout dexamethasone therapy and for 48 hours post-therapy.
• Infants served as their own controls to isolate the drug's effect.

Main Results:

• All infants showed a significant increase in systolic blood pressure (P < 0.01) during dexamethasone treatment.
• Systolic blood pressure remained elevated for at least 48 hours after cessation of therapy.
• Median maximum increase was 24 mmHg, occurring on day 4 of treatment; one infant developed hypertensive encephalopathy.

Conclusions:

• Dexamethasone therapy causes a significant and sustained increase in systolic blood pressure in very preterm infants with CLD.
• Close monitoring of blood pressure is essential throughout steroid treatment and for a period following its discontinuation.
• These findings underscore the importance of proactive management of steroid-induced hypertension in neonates.